Skip to main content
Platform for generating a seasonal vaccine for both influenza and coronaviruses

Platform for generating a seasonal vaccine for both influenza and coronaviruses

Unmet Need Similar to the flu vaccine, the need for seasonal post-immunization boosting to offer protection following COVID-19 vaccines remains possible. However, more than 8 percent of people who received a first dose of Pfizer…

Read More

Synthetic peptide adjuvants for mucosally-administered vaccines

Synthetic peptide adjuvants for mucosally-administered vaccines

Provided herein are peptides that have activity as mast cell activating proteins (MCAP), as well as compositions, adjuvant compositions, vaccines, and pharmaceutical formulations that include the peptides. Also provided are methods of using the peptides,…

Read More

Enhancing immune responses in a variety of applications with a lymph node targeting biodegradable nanoparticle

Enhancing immune responses in a variety of applications with a lymph node targeting biodegradable nanoparticle

Unmet Need While vaccines have resulted in plummeting mortality rates in the human population over the last century, significant challenges remain for which current vaccine formulations fall short. For example, current influenza vaccines are unable…

Read More

A therapeutic vaccine platform for treating influenza viruses

A therapeutic vaccine platform for treating influenza viruses

Value Proposition Influenza virus infections represent a substantial global burden on human health. Each year, it is estimated that influenza viruses cause up to 5 million severe infections globally, resulting in up to 645,000 mortalities.…

Read More

Replication competent bi- and tri-valent influenza viruses as vaccines

Replication competent bi- and tri-valent influenza viruses as vaccines

Value Proposition Influenza infection is a major public health concern, with an estimated 200,000 Americans hospitalized each year with flu or flu-related illness. The most effective method for flu prevention is vaccination, however, due to…

Read More

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us